Invitrogen acquires CellzDirect
Invitrogen, a provider of life science technologies for research, production and diagnostics, has announced a definitive agreement to purchase privately held American company CellzDirect for around $57 million.
CellzDirect provides hepatocyte-based cell products and related services used in the testing of new drugs. Primary human hepatocytes are the most accepted model for predicting a compound’s effects on enzymatic metabolism in the liver. Their products are mainly used by pharmaceutical and biotech companies in research and development.
“CellzDirect’s high-value products and services will greatly complement Invitrogen’s market-leading portfolio of complete cell systems, including primary cells, media, matrices and growth factors,” said Greg Lucier, Invitrogen’s chairman and CEO.
“The purchase of CellzDirect follows our strategy of investing in high growth areas of the market, specifically specialty cell systems.”
Noxopharm appoints Dr Olivier Laczka CEO
Australian clinical-stage biotech company Noxopharm Limited has appointed Dr Olivier Laczka as...
Nominations now open for the 2026 NMI Measurement Awards
Until 20 May, the National Measurement Institute (NMI) is accepting nominations for the 2026 NMI...
Australia to begin treaty negotiations on association to Horizon Europe
To give Australian organisations access to the world's largest pooled research fund in 2027,...
